Jazz Pharmaceuticals (JAZZ) Gross Profit (2010 - 2026)

Jazz Pharmaceuticals' Gross Profit history runs 17 years deep, the most recent figure standing at $934.8 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 17.85% year-over-year to $934.8 million in Q1 2026; TTM through Mar 2026 was $3.9 billion, a 8.2% increase from a year earlier, with the FY2025 full-year figure at $3.8 billion, up 3.89% from the prior year.
• Gross Profit declined to $934.8 million in Q1 2026 per JAZZ's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Gross Profit topped out at $1.0 billion in Q4 2025 and bottomed at $698.4 million in Q1 2022.
• The 5-year median for Gross Profit is $870.0 million (2023), against an average of $872.9 million.
• Across the five-year window, Gross Profit gained 27.83% in 2022 and declined 1.65% in 2025, its largest moves.
• Year by year, Gross Profit stood at $804.8 million in 2022, then gained by 12.42% to $904.7 million in 2023, then increased by 6.05% to $959.5 million in 2024, then climbed by 8.85% to $1.0 billion in 2025, then declined by 10.49% to $934.8 million in 2026.
• Per Business Quant, the three latest JAZZ Gross Profit figures stand at $934.8 million (Q1 2026), $1.0 billion (Q4 2025), and $997.2 million (Q3 2025).